MX2023011630A - Enlace autorreactivo activado por enzima que tiene propiedades fisicoquimicas y farmacologicas mejoradas. - Google Patents
Enlace autorreactivo activado por enzima que tiene propiedades fisicoquimicas y farmacologicas mejoradas.Info
- Publication number
- MX2023011630A MX2023011630A MX2023011630A MX2023011630A MX2023011630A MX 2023011630 A MX2023011630 A MX 2023011630A MX 2023011630 A MX2023011630 A MX 2023011630A MX 2023011630 A MX2023011630 A MX 2023011630A MX 2023011630 A MX2023011630 A MX 2023011630A
- Authority
- MX
- Mexico
- Prior art keywords
- enzyme
- reacting
- triggered self
- pharmacological properties
- improved physicochemical
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 3
- 108090000790 Enzymes Proteins 0.000 title abstract 3
- 230000001960 triggered effect Effects 0.000 title abstract 3
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000021615 conjugation Effects 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163167915P | 2021-03-30 | 2021-03-30 | |
| EP21305405 | 2021-03-30 | ||
| PCT/EP2022/058402 WO2022207699A1 (en) | 2021-03-30 | 2022-03-30 | Enzyme-triggered self-reacting linker having improved physicochemical and pharmacological properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011630A true MX2023011630A (es) | 2024-01-24 |
Family
ID=81580241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011630A MX2023011630A (es) | 2021-03-30 | 2022-03-30 | Enlace autorreactivo activado por enzima que tiene propiedades fisicoquimicas y farmacologicas mejoradas. |
Country Status (10)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12605459B2 (en) | 2020-07-13 | 2026-04-21 | Regeneron Pharmaceuticals, Inc. | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof |
| MX2024008640A (es) * | 2022-01-12 | 2024-07-24 | Regeneron Pharma | Analogos de camptotecina conjugados a un residuo de glutamina en una proteina y su uso. |
| AU2023231442B2 (en) * | 2022-03-11 | 2026-07-02 | Mablink Bioscience | Antibody-drug conjugates and their uses |
| JP2026504840A (ja) * | 2023-01-11 | 2026-02-10 | ジェンマブ エー/エス | リンカー、薬物リンカー、およびそれらの複合体、ならびにそれらを使用する方法 |
| WO2024222841A1 (zh) * | 2023-04-27 | 2024-10-31 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| AU2024263367A1 (en) * | 2023-04-27 | 2025-11-13 | CSPC Megalith Biopharmaceutical Co., Ltd. | Antibody-drug conjugate |
| EP4512427A1 (en) | 2023-08-25 | 2025-02-26 | Mablink Bioscience | Antibody-drug conjugates based on molecular glue degraders and uses thereof |
| EP4534102A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| FR3155708A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| FR3155709A1 (fr) * | 2023-11-27 | 2025-05-30 | Skymab Biotherapeutics | Conjugue anticorps-medicament et ses utilisations |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| WO2025230926A1 (en) * | 2024-04-29 | 2025-11-06 | Obi Pharma, Inc. | Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof |
| WO2026076215A1 (en) * | 2024-10-03 | 2026-04-09 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2026085106A1 (en) * | 2024-10-15 | 2026-04-23 | Solve Therapeutics, Inc. | Conjugates and uses thereof |
| WO2026086855A1 (zh) * | 2024-10-25 | 2026-04-30 | 石药集团巨石生物制药有限公司 | 一种靶向cdcp1的抗体药物偶联物及其用途 |
| WO2026112064A1 (en) * | 2024-11-20 | 2026-05-28 | Solve Therapeutics, Inc. | Conjugates of anti-5t4 antibodies with drugs and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775976B1 (fr) * | 1998-03-10 | 2000-06-02 | Fabre Pierre Dermo Cosmetique | Composition pharmaceutique ou cosmetique contenant un precurseur d'actif hydrolysable par la glucocerebrosidase |
| FR2960153B1 (fr) | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
| US20170014524A1 (en) * | 2015-07-15 | 2017-01-19 | The California Institute For Biomedical Research | Auristatin-antibody conjugates and uses thereof |
| CN107847605B (zh) | 2015-11-25 | 2021-12-24 | 乐高化学生物科学股份有限公司 | 包含分支接头的抗体-药物缀合物及其相关方法 |
| EP3700577A1 (en) * | 2017-10-23 | 2020-09-02 | Mablink Bioscience | Ligand-drug-conjugate comprising a single molecular weight polysarcosine |
-
2022
- 2022-03-30 MX MX2023011630A patent/MX2023011630A/es unknown
- 2022-03-30 US US18/285,175 patent/US20240216525A1/en active Pending
- 2022-03-30 EP EP22720929.3A patent/EP4313157A1/en active Pending
- 2022-03-30 JP JP2023559766A patent/JP2024512986A/ja active Pending
- 2022-03-30 WO PCT/EP2022/058402 patent/WO2022207699A1/en not_active Ceased
- 2022-03-30 AU AU2022248565A patent/AU2022248565A1/en active Pending
- 2022-03-30 KR KR1020237037385A patent/KR20230165288A/ko active Pending
- 2022-03-30 BR BR112023019495A patent/BR112023019495A2/pt unknown
- 2022-03-30 IL IL306050A patent/IL306050A/en unknown
- 2022-03-30 CA CA3215279A patent/CA3215279A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023019495A2 (pt) | 2023-11-07 |
| WO2022207699A1 (en) | 2022-10-06 |
| KR20230165288A (ko) | 2023-12-05 |
| JP2024512986A (ja) | 2024-03-21 |
| US20240216525A1 (en) | 2024-07-04 |
| AU2022248565A1 (en) | 2023-10-05 |
| EP4313157A1 (en) | 2024-02-07 |
| CA3215279A1 (en) | 2022-10-06 |
| IL306050A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023019495A2 (pt) | Ligante de autorreação induzida por enzima tendo propriedades fisicoquímicas e farmacológicas melhoradas | |
| CA2632451C (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| US7579318B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
| GEAP202416409A (en) | Exatecan derivatives and antibody-drug conjugates thereof | |
| MX2023002133A (es) | Nuevos derivados de psilocina que tienen propiedades de profarmaco. | |
| JP2010500967A (ja) | コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット | |
| JP2016512426A5 (cg-RX-API-DMAC10.html) | ||
| AU2019240611A1 (en) | Multi-Ligand Drug Conjugates and Uses Thereof | |
| TW203608B (cg-RX-API-DMAC10.html) | ||
| MX2024005546A (es) | Conjugados que comprenden fosforo (v) y una fraccion molecular de droga. | |
| JP2016512519A (ja) | 特定の細胞型の選択的死滅のための細胞標的化結合領域と志賀毒素aサブユニット領域とを含む細胞毒性タンパク質 | |
| MX2010009045A (es) | Derivados de indola sustituidos. | |
| IL281277B1 (en) | Compositions and methods for the treatment of viral infections | |
| PE20120514A1 (es) | Fusiones y conjugados de agentes insulinotropicos o farmacos incretina con anticuerpos dab anti-albumina serica | |
| EA201070739A1 (ru) | Полипептиды с усиленными противовоспалительными и сниженными цитотоксическими свойствами и связанные с ними способы | |
| ES2622228T3 (es) | Vacunas antivíricas dirigidas a células presentadoras de antígenos | |
| MX2025002793A (es) | Conjugado de anticuerpo y farmaco que comprende un inhibidor de nmt y sus usos | |
| NO20073756L (no) | Konjugater av et polypeptid og et oligosakkarid | |
| JP2021535209A5 (cg-RX-API-DMAC10.html) | ||
| Shafiee et al. | Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent | |
| MX2009009851A (es) | Conjugados de agonistas de oligomeros-opioides. | |
| MX2024010507A (es) | Conjugado anticuerpo-fármaco | |
| MY209735A (en) | Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof | |
| CA3127391A1 (en) | Method for preparing drug-linker mc-mmaf for antibody drug conjugate, and intermediates therein | |
| TW200706518A (en) | The dehydrogenation of mixed alcohols |